{{Drugbox
| verifiedrevid = 
| IUPAC_name = 4-[2-(4-Ethoxyphenyl)-4-methyl-1''H''-pyrrol-1-yl]benzenesulfonamide
| image = Apricoxib_structure.svg

<!--Identifiers-->
| CAS_number = 162011-90-7
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 9820073
| DrugBank = 
| ChemSpiderID = 7995822
| UNII = 
| KEGG = 
| ChEBI = 
| ChEMBL =

<!--Chemical data-->
| C=19 | H=20 | N=2 | O=3 | S=1 
| molecular_weight = 356.4387 g/mol
| smiles = CCOC1=CC=C(C=C1)C2=CC(=CN2C3=CC=C(C=C3)S(=O)(=O)N)C
| StdInChI = 1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23)
| StdInChIKey = JTMITOKKUMVWRT-UHFFFAOYSA-N
}}

'''Apricoxib''' is an experimental anticancer drug. It is a [[COX-2 inhibitor]] which is intended to improve standard therapy response in molecularly defined models of pancreatic cancer.<ref>{{cite journal | doi = 10.1158/1078-0432.CCR-12-0453 | title=Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer | journal=Clinical Cancer Research | date=2012 | volume=18 | issue=18 | pages=5031â€“5042 | first=A. | last=Kirane | pmid=22829202 | pmc=3777527}}</ref> Development was abandoned in 2015 due to poor clinical trial results.<ref>http://adisinsight.springer.com/drugs/800026002</ref>

==See also==
*[[Tilmacoxib]]
*[[cimicoxib]]
*[[NS-398]]
*[[Celecoxib]]

==References==
{{Reflist|2}}

{{Prostanoidergics}}

[[Category:COX-2 inhibitors]]
[[Category:Sulfonamides]]
[[Category:Abandoned drugs]]


{{pharma-stub}}